Fascin is highly upregulated in most invasive cancers and is increasingly recognized as a prognostic marker of metastatic disease and has thus received considerable recent attention as a potential therapeutic target (Bi et al., 2012; Gao et al., 2012; Hashimoto et al., 2006; Jayo and Parsons, 2010; Li et al., 2008). Here, FSCN1 is linked to metastatic neoplasm.